{"disease":{"id":"macula-edema","name":"macula edema"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"aflibercept","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"aflibercept","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"faricimab","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vabysmo","generic_name":"FARICIMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":62,"revenue":"5500","mechanism":"Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A."},{"drug_id":"eylea","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"faricimab-svoa","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VABYSMO","generic_name":"FARICIMAB-SVOA","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"Angiopoietin-2, Vascular endothelial growth factor A","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"lucentis","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"brolucizumab","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beovu","generic_name":"BROLUCIZUMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation."},{"drug_id":"beovu","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beovu","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-eqrn","indication_name":"Macular Edema Following Retinal Vein Occlusion (RVO)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Macular edema due to diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-eqrn","indication_name":"Diabetic Macular Edema (DME)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":20,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05966753","title":"Describing Patient With DME, Their Patient Journey and Disease Progression","phase":"","overall_status":"COMPLETED","enrollment_count":221004,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04935749","title":"Epidemiologic Assessment of Diabetic Retinopathy in Egypt Using Ultrawide Field Fundus Photographs","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Alexandria University","has_results":false},{"nct_id":"NCT03665090","title":"Shanghai Cohort Study of Diabetic Eye Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02194803","title":"Observation of Treatment Patterns With Lucentis in Approved Indications","phase":"","overall_status":"COMPLETED","enrollment_count":5778,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03094819","title":"PROTECT2: Diabetes Care - Eye Exam","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4500,"lead_sponsor_name":"Retinal Care Inc.","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06075147","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03161912","title":"A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease","phase":"","overall_status":"COMPLETED","enrollment_count":2481,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06686641","title":"Incidence of Macular Edema in a Uveitis Population","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT06213896","title":"Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images","phase":"","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi","has_results":false},{"nct_id":"NCT04432831","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1479,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04390126","title":"COVID-19 Related Lockdown Effects On Chronic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":1343,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT04620876","title":"Bimodal and Coaxial High Resolution Ophtalmic Imaging","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT01774474","title":"PRevention of Macular EDema After Cataract Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1127,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06491914","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1118,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05368623","title":"Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device","phase":"","overall_status":"COMPLETED","enrollment_count":1100,"lead_sponsor_name":"RETINA-AI Health, Inc.","has_results":false},{"nct_id":"NCT06957080","title":"A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1054,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT06439576","title":"Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06423274","title":"Comparing Artificial Intelligence for Assisted Diagnosis of Diabetic Retinopathy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04128150","title":"High Resolution Retina Imaging","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT05222633","title":"Anti-VEGF in Real-world","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Wenbin Wei","has_results":false},{"nct_id":"NCT05182580","title":"Bangladesh PRODUCTIVity in Eyecare Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":993,"lead_sponsor_name":"Orbis","has_results":true},{"nct_id":"NCT03622593","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":951,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03112005","title":"Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool","phase":"","overall_status":"COMPLETED","enrollment_count":942,"lead_sponsor_name":"Eyenuk, Inc.","has_results":false},{"nct_id":"NCT03622580","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":940,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04805541","title":"Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model","phase":"","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi","has_results":true},{"nct_id":"NCT05850520","title":"A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":892,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05472376","title":"Real-Life Study in Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":854,"lead_sponsor_name":"Kocaeli University","has_results":false},{"nct_id":"NCT06680817","title":"A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02850263","title":"A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema","phase":"","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06723288","title":"A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)","phase":"","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04740931","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":729,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00168298","title":"A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":668,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04429503","title":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":660,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT02425501","title":"Special Drug Use Investigation of EYLEA for Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":646,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04108156","title":"A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":634,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05158699","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":628,"lead_sponsor_name":"Luigi Rondas","has_results":false},{"nct_id":"NCT05080803","title":"Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome","phase":"","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"European School of Advanced Studies in Ophthalmology","has_results":false},{"nct_id":"NCT00168324","title":"A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01571557","title":"A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)","phase":"","overall_status":"COMPLETED","enrollment_count":573,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04543331","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04592419","title":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":568,"lead_sponsor_name":"Kodiak Sciences Inc","has_results":true},{"nct_id":"NCT03481634","title":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":566,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02581995","title":"Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04740905","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05130385","title":"High Resolution Optical Coherence Tomography","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT06850922","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":546,"lead_sponsor_name":"Genentech, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}